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INTRODUCTION 
The last decade has seen an explosion of activity in the clinical and research aspects of 
pediatric hepatology. The increased use of ultrasounds techniques and routine laboratory 
evaluation has drawn attention to several previously undiagnosed condition in childhood. 
The discipline has grown from a cataloguing of the many unique disorders that can occur 
during infancy and childhood to a more profound understanding of the genetic, biochemical, 
and virologic basis for many pediatric liver diseases.  
Nowadays hepatopathies still represent a significant cause of morbidity and mortality 
worldwide. However advances in diagnosis and treatment, particularly the successful 
development of transplantation, have dramatically improved the outcome for infants and 
children with liver disease,  so that many of them can now expect to grow into adult life. 
Sophisticated molecular genetic techniques have not only identified new genes and 
categorized rare defects, but have also given us an insight into pathophysiology and 
potential therapy.  National and international collaboration through clinical database has 
helped us refine diagnosis and treatment of several pediatric hepatic diseases. Differently 
from adults, the signs and symptoms of liver disease are often non specific and can vary 
greatly from child to child among the different liver diseases. This is one reason for which it 
can be hard to diagnose. As a result, liver disease may frequently be overlooked. Because  
most childhood hepatic diseases are progressive and life threatening, diagnosis failure can 
have devastating consequences. At present for most childhood liver diseases the cause is still 
unknown and is poorly satisfactory. The recognition of the pathogenesis of liver disease, the 
implications of innovative diagnostic techniques and therapies, the investigations of new 
clinical aspects during long-term follow-up,  and the necessity for multidisciplinary working 
are as important for general paediatricians as for pediatric gastroenterologists, surgeons and  
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hepatologists. The gratifying survival of increasing numbers of young people with liver 
disease into adult life means that it is essential also for adult practitioners with expertise in 
pediatric liver disease. Therefore, our research starts from the assumption that only 
knowledge of unexplored aspects can be an important tool for advancing into the 
management of hepatic disorders  in children. It should be a contribute to both provide a 
framework to understand pathophisiology of some hepatobiliary disorders and offer analyses 
of  their clinical-laboratory manifestations and the strategies for managing them. This 
project  might be also useful to create specific competences related to a integrated and 
multidisciplinary approach, as required in pediatric liver disease. Our study concerns three 
areas that still present several either pathogenetic or diagnostic uncertainties, focusing on the 
following aspects:  
1. Pathogenetic aspects of pediatric portal hypertension  
 - Do genetic prothrombotic risk factors play a role in pediatric portal vein thrombosis ? If 
so are they harmful also for other districts ? 
2. Diagnostic aspects of pediatric hypertransaminasemia and unconjugated hyperbilirubinemia 
- Which are the characteristcs of macro-aspartate aminotransferasemia (macro-AST) in  
pediatric age? Are current screening tests effective? Is this a “benign” condition? 
-  Is electrophisiological evaluation of Crigler Najjar syndrome an helpful tool to detect          
Neurotoxic complications of chronic hyperbilirubinemia ? 
3. Emerging complications of pediatric liver transplantation 
-  Is erythrocytosis a possible post-transplant complication also in liver recipients ? 
-  Does it exist a psychopatological risk in liver transplantated children ? 
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AIM 
The aim of our project has been triggered by limited existing scientific evidences vs. 
the increasing observation of children with these problems which in clinical practice lead to 
frequent  requests for specialist advices.  
In particular, the etiology of portal vein thrombosis in children affected by portal 
hypertension  is unknown. In this thesis, we aimed to demonstrate the possible role of 
genetic predisposing factors, which are still not clear in childhood. This in the perspective of 
individuating patients at higher risk for thrombotic events also in other disctricts.  
Isolated increase of serum AST levels is a relatively frequent laboratoristic feature in 
absence of clinical symptoms. This often leads to unexpensive, time-consuming and 
sometimes invasive procedures. Therefore, we aimed to characterize a large series of 
children with cryptogenic AST levels to demonstrate the dimension and nature of macro-
AST condition, and the accuracy of a simple screening test. The long term follow up was 
investigated as well to understand whether our previous observation that this is a benign 
condition is correct.  
Previous studies have investigated neurological aspects of genetic chronic non 
hemolytic hperbilirubinemia only in patients with severe forms of Crigler –Najjar Syndrome 
(type I). We aimed to assess the usefulness of neuroelectrophysiological studies also in 
patients with severe hyperbilirubinemia due to intermediate phenotype I/II Crigler-Najjar. 
This could be important to detect an early neurotoxic bilirubin effect without overt 
neurological damage, and to contribute for the appropriate timing of liver transplant.   
The purpose of the last two projects is to study two still poorly explored aspect of 
pediatric liver transplantation: the investigation and characterization of erythrocytosis, a 
post-transplant complication which has hitherto described only in kidney recipients, and of 
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the psycopathological risk. We believe that to increase knowledges in the management of 
children undergoing liver transplantation may be extremely important because they will 
ultimately lead to a better quality of life. In fact it is now becoming clear that liver transplant 
outcome needs to be judged using a measure incorporating not only survival rates but also 
other features including psychological and social well being as well.  
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1.1.   GENETIC PROTHROMBOTIC RISK FACTORS IN CHILDREN WITH 
          PORTAL VEIN THROMBOSIS    
 
INTRODUCTION 
Portal vein thrombosis (PVT) with cavernous transformation is an important cause of 
portal hypertension in children (1). It is associated with gastrointestinal bleeding mainly 
from oesophageal and/or gastric varices (2,3). The etiology of PVT in the majority of these 
chidren is unknown. The predisposing factors can be split into three groups: direct injury to 
the portal vein and consequent thrombus formation, as occurs in umbilical catheterization or 
in omphalitis; rare congenital malformations of the vascular system associated with other 
cardiovascular disorders; systemic causes such as neonatal sepsis, dehydration, multiple 
exchange transfusions and hypercoaugulable states (4).   
Genetic abnormalities affecting the physiologic anticoagulant system including 
deficiency of protein C (PC), protein S (PS) or antithrombin (AT), have been well 
estabilished as risk factors in adults (5). The recently described G1691A factor V (FVL), 
G20210A prothrombin (PTHR) and C677T methilenetetrahydrofolate reductase (MTHFR) 
mutations have also been reported as risk factors for venous thrombosis in general 
population (6-8)  and in adult PVT patients (9-11). Prevalence of genetic abnormalities in 
children and adolescents with PVT  has also been evaluated in few studies but the resulting 
data are not conclusive (12-17)  
Recent reports confirm that an activating tyrosine kinase mutation,V617F JAK2 is 
strongly implicated in the pathogenesis of myeloproliferative disorders (MPDs) that may be 
associated with increased rates of thrombosis (18). Because some adult PVT patients do not 
suffer from an overt MPD, this mutation is considered an other important risk factor in the 
development of PVT independently of MPD precence.    
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AIM 
The aim of this study was to assess the spectrum of genetic risk factors for portal vein 
thrombosis.  
 
 
PATIENTS AND METHODS 
Patients 
A 1-year prospective study (from October 2007 to October 2008) was carried out at the 
University of Naples “Federico II”, Italy. Nineteen patients (11 males, 8 females, mean age 
at study ± DS: 13.7 ± 3.7 years, range: 2.5 – 19.6 years) with portal cavernoma (mean age at 
diagnosis ± DS: 5.7 ± 3.9 years) were enrolled. Portal cavernoma was confirmed by 
angiography and  Doppler ultrasonography in 15 of them and only by Doppler 
ultrasonography in the remaining cases. Children with associated chronic liver and biliary 
diseases were excluded.   
 
Methods 
A clinical summary, with emphasis on family history of thromboembolic disease and 
on secondary risk factors such as umbilical vein catheterization in neonatal period, was 
obtained from all subjects.  
Patients also underwent a complete phisical examination. 
Blood cell counts, routine liver tests including aspartate and alanine amino transferase 
activities, γ-glutamyltransferase, total and conjugate bilirubin, coaugulation markers 
[prothrombin time (PT) and partial thromboplastin time (PTT)] were measured.  
Hyperhomocysteinema serum levels, PC, PS and AT activities were tested.  
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DNA was extracted from peripheral blood leukocytes according to standard protocols 
(18) to search G1691A FV, G20210A PTHR and  V617 JAK2 muations. C677T MTHFR 
polymorphism was analyzed.  
The study was carried out according to the principles of the Declaration of Helsinki. 
Informed consent was obtained from all subjects parents.  
 
 
RESULTS  
Doppler ultrasonography confirmed the presence of portal cavermona in all patients.   
No child had family history suggestive of thrombophilia. Twelve patients (63.1%) were 
found to have a history of umbilical vein catheterization in neonatal age, while the 
remaining 7 cases (46.9%) had not predisposing factors.  
Hematemesis from rupture of oesophageal varices was the most frequent presentation 
[10/19 patients (52,6%)] in the first eight years of life (range 4-12 years). Splenomegaly was 
discovered in 8/19 patients (42.6%); only one patient showed ascites (5.2%). Overall, 
recurrent gastrointestinal bleeding has been observed in 14 children (73.6%) and it mostly 
occured at a median interval of 1.2 year between the first and second event.   
Nine patients (47.3%) were receiving  beta-blockers (propanolol). Sclerotherapy or 
banding of varices were performed in all subjects. Seven patients (36.8%) had undergone 
surgical shunts: a superior mesenteric vein to intrahepatic left portal vein (Rex) shunt 
according to de Ville procedure in 2 of them, a portosystemic shunt in 4 and a spleno-renal 
shunt in the last one. Splenectomy had been made in 4 patients (21.1%).   
Twelve children (63.5%) presented splenomegaly with associated thrombocytopenia 
(<100.000/μl) and leucopenia (<1000/ μl) in 4 of them. Two patients (10.5%) had an 
isolated thrombocytopenia. 
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Liver function tests were usually normal except for occasional mild elevation in γ-
glutamyltransferase in 2 patients (10.5%).  
Increased levels of total bilirubin were discovered in four patients (21.1%) and were 
due to Gilbert Syndrome, a condition that may be associated to PVT.    
Three children (31.5%) presented longer PT (mean values ± SD: 64.1 ± 2.0 %); all 
remaining patients had normal coagulation values.   
PC and PS activity was decreased in 8 patients (42%) [mean values ± SD: 59.2±4.5%, 
range: 49.5-63.5%] and in 7 (36.8%) [mean values ± SD: 55.1±7.9%, range: 40-64%],  
respectively. Serum AT activity was normal in all cases.  
Heterozygous G1691A FV mutation and heterozygous G202210A PTHR mutation 
were found in 2 of 19 (10.5%) and in other two patiens (10.5%), respectively. None carried 
V617F JAK2 mutation, while only one (5.2%) hyperhomocysteinemic patient was  
homozygous for C677T MTHFR mutation (table 1).  
As shown in table 2, four (1 FV, 2 PTHR and 1 MTHFR) out of 12 patients (33.3%)  
with PVT and history of umbilical vein catheterization and only one (1 FV) out of 7 patients 
(14.3%) with idiophatic PVT had a genetic thrombophilic state.  
 
  
DISCUSSION 
In most of the children affected by portal hypertension, a thrombus in the portal vein 
with resulting cavernous transformation is the leading cause. Usually children come to 
attention with gastrointestinal bleeding within the first decade of life. Diagnosis of PVT 
needed invasive techniques such as splenic portography, but the introduction of Doppler 
ultrasound examination may lead to early diagnosis. Outcome of pediatric patients with PVT 
depends on the control of gastrointestinal bleeding from varices. Use of beta-blockers and 
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recent advances in the non surgical treatment of gastroesophageal varices have resulted in 
remarkable improvement in the clinical course of the patients.  
 Etiology and pathogenesis of PVT are unclear. It was initially proposed that umbilical 
vein catheterization in the neonatal period is responsible in almost half of the cases of newly 
diagnosed portal vein obstruction in children (20). Regarding umbilical vein catheterization, 
the predisposing factors for the development of PVT are represented by catheter 
misplacement, catheter dwell time over 3 days, trauma on catheter insertion and type of 
solution infused (20,21). It has been demonstrated that an appropriate placement of an 
umbilical vein catheter in neonatal age is associated with an acceptably low risk of PVT 
justifying the use of this procedure for fluid administration in critically ill term and preterm 
infants (22).  
In recent years, the presence of congenital prothrombotic conditions has been 
considered an interesting hypothesis for the causation of PVT. Children with PVT display a 
reduction in PC, PS and AT activies as demonstrated by Dubuisson et al (12), but the 
absence of similar findings in all parents suggested that coagulation inhibitors deficiencies 
are not likely to be of genetic origin.  Low values of PC, PS, and AT could be a reflection of 
an affected liver synthetic function or of their increased clearance and consume by the 
cavernoma itself.(12). Pinto et al (13) and Seixas et al (14) also found that hereditary PC and 
PS deficiency is not an etiological factor for PVT in chidren. 
In agreement with these previous studies (12,13), PS and PC activities of our series 
were reduced in a relevant percentage of both groups of patients with idiopathic and post 
catheterism PVT  (about one third of cases). PC was reduced in a lower number of patients 
than that reported by Chillemi et al (17)  but this difference might depend on the fact that the 
authors did not include patients who underwent derivative surgical therapy. However may 
be a consequence also of other factors that at moment one cannot explain.                   
Although G1691A FV, G20210A PTHR and C677T MTHFR mutations have recently been 
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reported as risk factors in general population and in adult PVT patients (6-8, 9-11), their 
association with PVT in pediatric age is questionable. In contrast with El-karasky (16) and 
Chillemi et al (17) who proved a congenital condition of thrombofilia, characterized by 
mutations in FV and PTHR genes in children with PVT, other studies (4,14,15) failed to 
demonstrate a similar correlation. No data on the role of MTHFR mutations in pediatric 
PVT development are avalaible.  
By large-scale epidemiological studies, prevalence of heterozygous G1691A FV 
mutation has been estimated to be 3-5 % of general population while heterozygous 
G20210A PTHR mutations are 2 to 3 % (6,7). So, in our series a congenital condition of 
thrombophilia namely regarding FV and PTHR was found in 5 of 19 children (26%), more 
frequently than the normal population, suggesting  that hereditary prothrombotic disorders 
could be important in the development of pediatric  PVT. Homozygous C677T MTHFR 
mutation was found in one patient (5%), but this is not relevant because of the large 
prevalence of homozygous state in the general population (4-26%) (8). It is interesting to 
note that a thrombophilic condition has been discovered mostly in the group of patients with 
a history of umbilical vein catheterization in the neonatal period. These data may indicate 
that pre-existing stress of portal vein by catheterism seems to have facilitated establishment 
of PVT in genetically predisposed individuals.  
We extended our procoagulant screen to include V617F JAK2 analysis. This mutation 
leads to constitutive activation of JAK2, a cytosolic tyrosine kinase that transduces signals 
induced by haemotopoietic growth factors including erythropoeitin and stem cell 
proliferation. It was reported in more than 90% of patients with PV and half of patients with 
ET (22). Since it is well-known that PVT may be an early or presenting complication of an 
undiagnosed MPD, several groups have examinated V617F JAK2 in adult patients with 
idiopatic PVT. They found that V617F JAK2 mutation occurred in these patiens in a 
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percentage ranging from 17.2% to 45% independently of the presence of overt MPDs 
(18,24, 25).  
The role of V617F JAK2 in development of  pediatric PVT has been investigated only 
in one study (4). V617F JAK2 mutation screening was found to be negative in all 30 
children with PVT tested. In keeping with these results, none of our patients carried V617F 
JAK2 mutation, but both these 2 pediatric series were extremely small. 
    In conclusion, a congenital prothrombotic condition observed in 26% of our children 
indicates that thrombophilic mutations may be involved in pediatric PVT. Preexisting stress 
of portal vein by catheterism might facilitate establishment of PVT in genetically 
predisposed individuals. We suggest that large scale studies are therefore still necessary to 
gain a better insight into pediatric PVT pathogenesis. Further evaluation of the V617F JAK2 
mutation that has hitherto scarcely been investigated in the pediatric age needs to be 
included. Investigation should be extended also to JAK2 exon 12 mutations, which have 
most recently been shown to be possibly involved in both polycythemia vera and idiopathic 
erythrocytosis (26). Understanding of thrombophilic genetic factors predisposing to PVT 
could be helpful to identify at risk patients subgroups and prevent other possible thrombotic 
events also in different districts. 
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TABLE 1. Coagulation disorders and genetic mutations in patients with PVT 
                         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mutations percentage of thrombophilic factors are compared with that of general 
population as reported in literature: 
 
1. *Hermann FH, Koesling M, Schroder W et al. Prevalence of factor V Leiden 
mutation in various populations. Genet Epidemiol 1997;14: 403-11. 
2. **Rosendaal FR, Doggen CJM, Zivellin A et al. Geographic distribution of the 
20210G to A prothrombin variant. Thromb Haemost 1998; 79:706-8. 
3. ***Wilchen B, Bamforth F, Li Z et al. Geographical and ethnic variation of the 
677>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): finding 
from over 7000 newborns from 16 areas worl wide. J Med Genet 2003; 40: 619-
25. 
4.  § Colaizzo D, Amitrano L Iannaccone L et al. Gain of function gene mutations and 
venous thromboembolism: distinct roles in different clinical setting. J Med Genet 
2007; 44: 412-16. 
 Patients with    
normal 
parameters 
 
Patients  with 
abnormal 
parameters 
Mean 
values 
Range Normal  
values 
PT   (%) 
 
16 3 (15.7%) 64.1 ± 2.0 62.70-66.50 70-130 
PTT (“) 
 
19 0 0  26- 44 
PC   (%) 11 8 (42%) 59.2 ± 4.5 49.59-63.56 70-120 
PS    (%) 12 7 (36.8%) 55.1 ± 7.9 40-64 70-140 
AT   (%) 19 0 0  70-120 
FV 
(G1691A) 
17 2 (10.5%) 
Heterozygous 
 
  3-5% 
Heterozygous* 
 
PTHR 
(G20210A) 
17 2 (10.5%) 
Heterozygous 
  2-3% 
Heterozygous** 
 
MTHFR 
(C677T) 
18 1 (5.2%) 
Homozigous 
     4-26% 
Homozygous*** 
 
JAK2 
(V617F) 
19 0   0/286§ 
 21 
  
TABLE 2. Coagulation disorders and genetic mutations in patients with Idiopathic Portal 
Vein Thrombosis PVT (IPVT) and patients with post umbilical vein catheterization Portal 
Vein Thrombosis (PUVC - PVT) 
 
 
 
IPVT patients 
with abnormal  
parameters 
(n=7) 
 
Mean 
values 
PUVC– PVT  
patients 
with abnormal 
parameters 
(n=12) 
 
Mean 
values 
PT (%) 
 
2 (28.5%) 64.6 ± 2.7 1 (8.3%) 63.2 
PTT (“) 
 
0 0 0 0 
PC (%) 
 
4 (57.1%) 57.8 ± 6.1 4 (33.3%) 60.5 ± 2.22 
PS (%) 
 
4 (57.1%) 56.7 ± 4.5 3 (25%) 53 ± 12.12 
 
FVL 
(G1691A) 
 
 
1 (14.2%) 
Heterozygous   
 
1 (8.3%) 
Heterozygous 
 
3-5% 
Heterozygous 
PTHR  
(G20210A) 
 
0  2 (16.6%) 
Heterozygous 
2-3% 
Heterozygous 
MTHFR  
(C677T) 
0  1 (8.3%) 
Homozygous 
4-26% 
Homozygous 
 
JAK2 
(V617F) 
 
0 
  
0 
 
0/286 
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2.1. PREVALENCE MACRO-ASPARTATE AMINOTRANSFERASEMIA 
(MACRO-AST)AND LONG-TERM COURSE OF IN CHILDREN 
 
 
Macro-AST has became an increasingly identified but still poorly studied 
cause of elevated serum aspartate aminotransferase activity. It has been found in 
diseases such as hepatitis, various malignancies and autoimmune defects. 
However, this phenomenon is present in otherwise healthy subjects, in particular 
in pediatric age. As yet, it is not clear whether the macro-AST is persistent, nor 
is the pathogenesis or the prevalence of this rare condition clear.  
       Polyethylene glycol (PEG) precipitation is a simple test which can 
identify macro-AST but references ranges of PEG-precipitable activity (%PPA) 
are not well established, so that confirmation by electrophoresis-the gold 
standard diagnostic test- is needed.  
Aim of this project is therefore to investigate the prevalence, association 
with clinical conditions, and long-term course of macro-aspartate 
aminotransferase (macro-AST). 
We studied for the first time a large series of healthy children with an 
isolated cryptogenic elevation of serum AST.  
Macro-AST has been found in over one-third of our children. The cases 
reported suggest that is a benign phenomenon. We found that the suspicion of 
macro-AST should be raised not only in subjects with high AST levels but also 
in those with AST levels slightly higher than the normal range, after exclusion of 
other known causative factors of increased transaminase values. Although it is 
not clear what causes the formation of macro-AST, or which favours or causes 
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its appearance or disappearance in the blood, it may persist for years but may be 
also a transient phenomenon in some patients. The % precise PPA thresholds 
identified in the present study shows that it can be used as a screening test and 
that electrophoresis is helpful only to confirm positive and ambiguous results. 
These data may help paediatricians when they come across patients with an 
isolated increase of AST which does not fit the clinical condition, to avoid time-
consuming, expensive and  invasive procedures.  
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2.2. CLI NI C AL UTI LI TY O F EL EC TRO PH Y SI O LO GI C  
EVALUATION IN CRIGLER-NAJJAR SYNDROME 
 
Crigler Najjar (CN) syndrome is an extremely heterogeneous condition 
with high grade increase of neurotoxic unconjugated bilirubin. Severe forms 
(type I CN) need liver transplantation (OLT) to survive. Sometimes clinical 
picture of mild forms (type II CN) overlaps with those of severe forms leading to 
an intermediate variety (type I/II CN) that represents a diagnostic and 
therapeutic challenge. In fact, asymptomatic patients with borderline 
hyperbilirubinemia values may suddenly present with severe neurological 
damage during adolescence or early adulthood. In these cases neurophysiologic 
features have not been characterized. So far, it is therefore not clear how to 
monitor long-term neurological aspects of CN patients in cases with raised 
bilirubin levels and not yet overt neurological damage to estabilish the 
appropriate timing of OLT.  
In the series studied by us only electroencephalogram (EEG) and visual 
evoked potentials (VEPs) seemed to be correlated wih high bilirubin levels. 
Since VEPs are a quantitative test, we propose this test as a useful tool to 
monitor the neurotoxic effects of hyperbilirubinemia. Differently from brainstem 
auditory (BAEPs) and  motor (MEPs) evoked potentials, EEG and VEPs 
contribute to detect and monitor bilirubin neurotoxic effects and may play a 
decisional role alerting physicians for OLT evaluation in those cases of severe 
hyperbilirubinemia without clinical findings of overt neurologic damage. 
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3.1. POST TRANSPLANT ERYTHROCYTOSIS AFFECTING FIVE 
LIVER RECIPIENTS  
 
 
INTRODUCTION 
 
Erythrocytosis is a quite common complication of renal transplant 
recipients with a prevalence on the order of 10-15% (1) varying from as low as 
3.2% in the pediatric age (2) to as high as 20.2% in adults (1,3), and has not been 
reported in other types of organ transplantation. A transient  increase in 
endogenous erythropoietin levels (EPO) after 12-48 hours from orthotopic liver 
transplantation (OLT) has been described  in six out of ten liver transplanted 
children (4). Its recognition and treatment are important for maintaining 
hematocrit (Hct) below the critical threshold of  51% to reduce the clinical 
symptoms and/or to minimize the possible risk of hyperviscosity related 
thrombosis especially at sites of vascular anastomosis (1,5-7). The pathogenesis 
is multifactorial and still poorly understood. EPO, the renin-angiotensin system, 
male gender and renal cysts are some of the factors that have been proposed to 
play a role in post-renal transplant erythrocytosis (1,3,7-10).  
 
AIM 
To investigate wheter and why erythrocytosis may develop also in the long 
term course after orthotropic liver transplantation (OLT).  
 
 
 
 47 
  
 
PATIENTS AND METHODS 
We retrospectively evaluated the occurrence of erythrocytosis in ninety 
Italian liver transplanted children (F:M=42:48, age: 12.8± 6.7 years ) followed 
up at our department. Mean age (±SD) at liver transplantation was 3.2 ± 3.6 
years (range 0.2 – 12.5). Main  
OLT indication was Biliary atresia (70%). Primary immunosuppressor was 
Tacrolimus in 64 (71.2%) and Cyclosporin A (CsA) in 26 (28.8%) patients. 
Family and personal history, complete physical examination, symptoms possibly 
related to erythrocytosis (e.g. headache, malaise, dizziness), red blood cells 
(RBC) count, hemogobin  levels (Hb), Hct, calcineurin inhibitors levels, hepatic 
and renal function tests including  ultrasonographic (US) parameters were 
recorded from their files. 
Erythrocytosis was suspected based on increased Hb and Hct values 
(>mean +2SD or >97th percentile) in two separate blood counts (11). Age-
specific reference ranges have been considered (12). Patients with erythrocytosis 
underwent diagnostic tests and procedures aiming to identify possible causes of 
an absolute erythrocytosis.  
Therefore EPO receptor mutation and JAK2 V617F mutation, the last 
recently reported in the majority of adult patients with Polycytemia Vera (13), 
were searched. Exon 12 of JAK2 was also analyzed to investigate the possible 
mutations described in patients with Polycytemia Vera who did not have V617F 
mutation (14) Renin serum levels, high oxygen-affinity haemoglobins (defect of 
α and β globin chains) and gene mutations of the oxygen sensing pathway (VHL, 
PHD2, HIF-2α) were evaluated as well. Central hypoxia driven processes due to 
smoke, high altitude, chronic lung disease, sleep apnea and congenital cyanotic 
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heart disease were investigated by personal-history, arterial blood gas analysis, 
chest x-ray, spirometry,otorhinolaryngologic evaluation and echocardiogram. A 
total-body computed tomography (CT) was obtained to exclude malignant and 
non-malignant tumours associated to a pathological EPO production only in 
patients with increased EPO levels. 
    
RESULTS 
None of 90 children had elevated pre-OLT Hct values, and no renal cysts 
were found at routine abdominal US and CT performed before OLT. As shown 
in table 1, four male and one female patients (5.5%) showed erythrocytosis at 
14.8 ± 4.3 years of age (RBC count, Hb and Hct above normal values). The 
mean time (±SD) from transplantation to diagnosis  of hematological disorder 
was 9.1 ± 5.1  years. Extended family history was negative for kidney cystic 
diseases. All brothers and sisters, and both parents of the five patients had 
normal complete blood counts and renal ultrasonographic images. None of the 
patients were smokers or lived at high altitude. None of them was affected by a 
congenital  cyanotic heart disease as demonstrated by routine echocardiograms 
performed before OLT. Physical examination of the patients did not show 
relevant abnormalities. Platelets and white blood cell counts, RBC morphology, 
mean corpuscular volume, and spleen size were within normal ranges except for  
two patients (CD, AL) who had  splenomegaly and a progressive decrease of 
platelet count. We did not find V617F and exon 12 mutations of JAK2. EPO 
receptor abnormalities were absent in all patients. Renin serum levels, Hb 
electrophoresis, mutations of oxygen sensing pathway genes (VHL, PHD2, HIF-
2α), repeated arterial blood gas analysis, chest x-ray, spirometry were negative 
or within normal limits. The profile of biochemical tests to survey the function 
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of other principal body organs and systems including liver and kidney was 
normal (table 1; figure 1).  
Three of the five patients (NG, RC, CD) were asymptomatic and developed 
erythrocytosis 8.5, 4.1 and 14.1 years  post-OLT, respectively. Their EPO levels 
were within normal limits (figure 1). Kidney ultrasonography and CT were 
negative for renal cysts. Primary immunosuppressor  was Tacrolimus in the first 
two, whole blood levels being within normal limits (range 4-6 ng/ml) (table 1). 
In the third patient (CD) primary immunosuppression consisted initially in Csa 
and after 9 years from OLT it was substituted by Tacrolimus because of early 
signs of chronic rejection. During  follow up, no symptoms related to 
erythrocytosis were reported in all and Hct values fluctuated ranging between 
48.3% and 52.7% with the exception of the last case (CD) who showed 
increased Hct values ( >50%) in three separate blood counts in presence of Hb 
values persistently increased (mean ± SD: Hb 16.9 ± 0.6 g/dl). The only one 
female patient (AL), who was taking Tacrolimus, developed erythrocytosis 
earlier than others (i.e. 4.4 years after OLT). Her Hb (mean Hb ± SD: 15.9 ± 0.4 
g/dl) and Hct values (mean Hct ± SD: 45.5 ± 1.1 %) were increased referring to 
age-specific reference ranges (12) such as  EPO levels that were fluctuating and 
sometimes elevated  ranging from to 13-25 mU/ml. However there was no 
evidence of renal cysts at US investigation (table 1; figure 1). In the last six 
months a transient isolated and asymptomatic hypoxia was occasionally 
discovered by arterial blood analysis. Oxygen saturation level (SaO2), 
inflammatory and infectious parameters, chest x-ray, spirometry and 
echocardiogram were negative. As shown in Table 1, the fourth  patient (RT) 
developed late clinically symptomatic erythrocytosis at age fifteen (14.5 years 
post-OLT). EPO serum levels were twofold the upper normal limits. Two years 
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before, multiple cysts with a diameter ranging from 0.3 to 0.6 mm in both 
kidneys appeared at ultrasonography. A CT total-body resulted negative for 
aberrant EPO producing mass and confirmed renal cysts. Primary 
immunosuppressor was CsA, and its whole blood levels were within therapeutic 
range for post-transplant age (ranging 70-100 ng/ml, monoclonal fraction). Two 
months after erythrocytosis onset he had to switch to Tacrolimus because of 
mild signs of rejection observed at a routinely planned liver biopsy in the 
presence of normal liver function tests.  
During a five-year follow up, several phlebotomy (n=10) and 
erythroapheresis (n=14) sessions were necessary to maintain Hct in a safe range 
and to reduce clinical symptoms. An ACE inhibitor (Ramipril) was furthermore 
added to the treatment because of persistence of clinical and laboratory 
abnormalities. Response was initially poor. At age 20, MRI showed enlarged 
cysts with major diameter of 16 mm. In the last year EPO levels reached 
approximately four folds the upper normal limits. However Hct and Hb levels 
become normal after 18 months so that phlebotomy or erythroapheresis 
procedures were not necessary. Present EPO level is still high (31.3 mU/ml)   
 
 
DISCUSSION 
Post- transplant erythrocytosis is a complication that has hitherto been 
described only in renal graft recipients, mainly adults (1-3,7). A transient 
erythrocytosis condition has been reported only in one series of children soon 
after liver transplantation (OLT) (4). Here we describe five cases of 
erythrocytosis developing during the long term follow-up after OLT.  
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Differently from renal transplanted patients, where erythrocytosis develops 
during the first years of follow-up (1), our patients presented this condition later 
(4.1-14.5 years after OLT). 
The pathogenesis of post-transplant erythrocytosis remains still 
incompletely understood and it is believed to be multifactorial (1,3, 7-10). In 
keeping with post-renal transplant erythrocytosis reports (1,7,9) our 
symptomatic patient showed high EPO levels, contrary to expectation from the 
normally negative feedback loop between Hct and EPO secretion (1). Because 
renal function was normal and no subclinical hypoxia was detected by repeated 
arterial blood gas analysis, we believe that excess EPO production might be 
related to the presence of the renal cysts. It is unclear whether renal cysts 
produce EPO or simply cause local ischemic injury by compressing adjacent 
renal tissue leading to local renal hypoxia and to increased EPO production 
(7,11). The possible association between renal cysts and erythrocytosis is 
supported by the resolution of this condition after drainage or resection of cysts 
in some case reports of secondary polycythaemia which as been decribed 
described in non-transplanted patients (15,16). In a large series of 108 liver 
transplanted children an high incidence (30%) of post-OLT acquired renal cystic 
disease was detected by CT scan (17). A lower incidence (11%), comparable to 
our results (8.8%), was observed with ultrasonography (US) in another recent 
series of 235 OLT-children (18). The different incidence of renal cysts is 
probably due to the less sensitivity of US vs. CT scan (17). Unexpectedly, no 
mention of erythrocytosis was made in these studies.  
In our remaining clinically asymptomatic patients who had normal EPO 
levels and no renal laboratory and ultrasonographic alterations, the mechanisms 
underlying erythrocytosis remains unknown. In these male patients renin-
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angiotensin system  and endogenous androgens might play a role. These 
hormones may stimulate directly the erythroid progenitor lines or may augment 
the production of other erythropoietic factors (1). Abnormal erythroid precursor 
sensitivity to EPO might also be implicated (6,10). It is interesting to note the 
case of the young female patient who had increased and fluctuating  EPO levels 
with a transient asymptomatic hypoxia occasionally discovered by arterial blood 
gas analysis. However we do not know if  a correlation between these laboratory 
data and the increased EPO serum levels exists.In all cases, most causes of  
erythrocythosis were ruled out by a number of tests performed during follow-up. 
In the majority of renal transplant studies erythrocytosis was more common 
in male patients (1,3,15) and in those who received CsA (1,3). In our series 
erythrocytosis developed in four male patients: two of them were receiving 
Tacrolimus, while the other two patients at first were receiving CsA. This may 
suggest that in OLT recipients Hct abnormalities may develop and go on 
independently of the type of  immunosuppressive therapy. The possible 
responsibility of immunosuppressive agents remains uncertain also because the 
speculated drug related effect developed several years after OLT. 
In adults,  erythrocytosis treatment is considered necessary to reduce the 
potential thromboembolic risk secondary to blood hyperviscosity (1,5-7). 
Phlebotomy/erythroapheresis is the first line standard treatment (18). Some 
drugs, such as angiotensin converting enzyme inhibitors, angiotensin-II receptor 
antagonist and adenosine receptor antagonist have been reported to reduce Hct 
elevated values in kidney recipients (1,19). In particular it has been 
demonstrated that Ramipril may be effective in the post- renal trasplant 
erytrocythosis; low doses normalized Hct in most patients (19). In our 
symptomatic patient phlebotomy/erythroapheresis were well tolerated and no 
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severe iron deficiency developed. Because of persistence of clinical and 
laboratory abnormalities, Ramipril was introduced. Although its response was 
initially modest, Hct and Hb levels become normal after 18 months of therapy. 
In the other patients, due to absence of clinical symptoms and to fluctuations of 
Hct values, no therapy has still been started. Pending more definite management 
criteria (6), a longer follow up was thought to be necessary to evaluate the 
course of the erythrocytosis and the need for treatment.                                                           
In conclusion, we have shown that erythrocytosis may be a rare and late 
complication in patients who underwent liver transplantation in the pediatric-
adolescent  age. The pathogenesis remains still incompletely understood. EPO, 
male gender, and renal cysts may probably play a role. Future research may still 
investigate on JAK2 exon12 mutations, which have most recently been 
described both in polycythemia vera and idiopathic erythrocytosis (14).               
 Epidemiological studies on erythrocytosis in children overall, and in post 
OLT patients in particular, are necessary to establish whether a casual (as seen in 
post renal transplantation) rather than a causal association may exist between 
this hematological abnormality and liver transplantation.  
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TABLE 1 Demographic, clinical and laboratory findings of five patients who developed 
post-liver transplantation erythrocytosis (PTE) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient NG    RC    CD AL RT 
Gender 
 M M M F M 
OLT indication 
 
Crigler 
Najjar I 
Biliary 
Atresia 
Biliary 
Atresia 
Biliary 
Atresia 
Biliary 
Atresia 
OLT Age (yr) 10.3 12.5 1.9 3.1 0.8 
Age at PTE 
diagnosis (yr) 18 16.6 16 7.5 15.3 
Immunosuppressor  
at PTE diagnosis Tacrolimus Tacrolimus Tacrolimus Tacrolimus Cyclosporin A 
Hct pre-OLT (%) 37.2 37.1 31.1 35 32.8 
Hct at  PTE 
diagnosis (%) 51.5 51.7 47.7 47.8 53.1 
EPO at  PTE 
diagnosis (mU/ml)  
(n.v. 3-20) 
14 13 13.8 17.5 38 
Hb  pre-OLT (g/dl) 12 12.6 10.2 12 10.5 
Hb at PTE 
diagnosis (g/dl) 17.6 17.7 17.3 16.3 18.0 
RBC  pre-OLT 
(x 106/µL) 5.12 5.20 3.66 4.14 3.12 
RBC  at  PTE 
diagnosis 
(x 106/µL) 
6.14 6.17 5.20 5.45 5.68 
Creatinine 
clearance at PTE 
diagnosis (ml/min) 
119 116 101.7 72.6 91 
Renal US/TC at 
PTE diagnosis Normal Normal Normal Normal 
Multiple cysts 
in both 
kidneys 
Signs and 
symptoms  
related to PTE 
No No No 
No/transient 
asymptomatic 
hypoxia 
Yes 
(headache, 
malaise, 
dizziness, 
hypertension) 
 57 
  
 
 
 
FI
G
U
R
E
 1
. H
ct
 a
nd
 E
PO
 ti
m
e 
co
ur
se
 v
al
ue
s o
f 5
 p
at
ie
nt
s w
ho
 d
ev
el
op
ed
 p
os
t-l
iv
er
 tr
an
sp
la
nt
at
io
n 
er
yt
hr
oc
yt
os
is 
 
 
 
 
 
 
 
 
 
 59 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 60 
  
 
 61 
  
 62 
  
 
 
3.2 SELF CONCEPT AND PSYCHOPATOLOGICAL RISK IN LIVER 
TRANSPLANTATED CHILDREN  
 
INTRODUCTION 
 
In the last 20 years, liver transplantation has become the treatment of 
choice for several pediatric liver diseases that progress to end-stage liver failure 
(1). Graft and patient survival continue to improve due to developments of 
medical and surgical management, new immunosuppressant drugs, higher organ 
availability and control of post-operative complications (2). Currently patients'  
long-term survival rates are reported to be between 80 and 90% (1-4). The 
possibility of prolonging recipient's life expectancy triggered several studies 
which focus not only on organic problems but also on neurological and 
psychological aspects of childhood orthotopic liver-transplantation (OLT) (5).  
It has been reported that children who have undergone OLT may present 
emotional and behavioural disturbances for a long period of time after 
transplantation and it was higher than in children with chronic liver diseases 
(5,6). Due to small size of  studied series, several uncertainties regarding 
psychological problems in these patients and the need to differentiate their 
disturbances from those related to the chronic liver disease itself however still 
exist. Evaluation of self-concept, an area poorly explored in OLT recipients (7), 
needs to be studied as well.  
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AIM 
To assess psychopatological risk and self-concept in liver transplantated 
children as compared to age matched controls with stable chronic liver disease.  
 
 
PATIENTS AND METHODS 
 
 
Patients 
29 OLT patients with a mean age of 11.7±3.9 years (range 6–18) have been 
enrolled for this study. Patients have been compared with an age matched 
control group (CTRL) affected by stable chronic liver disease. All children were 
regularly attending school. No patient or family was or had been involved in 
longterm or intensive psychosocial support programs during any phase of the 
transplantation process. 
Methods 
The assessment included individual sessions and testing procedures as 
follows: 
1.  CBCL (Child Behaviour Checklist) for assessing behaviour problems 
and competences of children aged 4–18 years (8,9). It consists of 113 
items, completed by parents, listing a range of behavioural and 
emotional symptoms, rated using a semiquantitative scale. The author 
of this test developed a model consisting of eight subscales or 
Syndromic Scales: Withdrawal, Somatic Complaints, 
Anxiety/Depression, Social Problems, Thought Problems, Attention 
Problems, Delinquent- Aggressive Behaviour, as well as a scale for 
Sex Problems. The test, includes, moreover, three additional scores: 
one for Internalization, one for Externalization and one for Total 
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Problems. Competences are assessed by other three scales: Activities, 
Social Function and School. A total score is obtained by summing up 
these scales. CBCL profiles enable to discriminate Normal, Borderline 
and Clinical children (8,9).  
2.  TMA (Test Multidimensionale dell'Autostima) is the italian version of 
the MSCS (Multidimensional Self Concept Scale) (10). It consists of 
150 Likert-type items and was designed for either individual or group 
administration. The TMA reflect a context-dependent, 
multidimensional self-concept model. TMA assesses self-concept in 
each of the following six subdomains: Social, Competence, Affect, 
Academic, Family and Physical. The TMA manual reports .98 total 
scale internal consistency and .90 stability (i.e., 2 weeks). TMA 
subscale internal consistency ranges from .87 to .97, and subscale 
stability coefficients range from .73 to .81. The validity of TMA and 
its multidimensional, context-dependent model have been studied 
among runaway adolescents, with respect to students' age, race, and 
gender, as the model and test relate to children sociometrically 
determined social status (10).  
Statistical analysis 
Difference between the number of patients with normal results obtained by 
CBCL and TMA scores, and patients with borderline and pathological results 
has been calculated by exact Fisher test (EFT). A significative value has been 
identified by p value < 0.05.  
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RESULTS  
Patients’ mean age at the time of OLT was 3.2 ± 3.5 years (range 0.7–9.8). 
The mean time elapsed since transplantation was 5.1 ± 4.5 years (range 0.7–
15.8). Biliary Atresia was the main indications to OLT (90%). 
CBCL test and TMA results are shown as follow:  
1.  CBCL test results.  
 Total Problems Scale showed a statistically significant higher 
percentage of results within the pathological range in the OLT group 
(52%) vs CTRL group (17%) (p = 0.03). Total Competence Scale 
showed results within the pathological range in both groups (88% and 
92% in OLT and CTRL groups, respectively) with no statistically 
significant difference (p = 0.67). The increased number of 
pathological results in the Total Competence Scale was preminently 
due to the Activity section. 
2.  TMA results.  
 With regard to Self-Concept there were no statistically significant 
differences between the two groups concerning Social, Competence, 
Affect, Family and Physical subdomains. In the Academic subdomain 
there was a statistically significant difference in the percentage of 
patients showing a lower self-concept (50% and 9% in OLT and 
CTRL groups, respectively) (p = 0.025). 
 
DISCUSSION  
A mild cognitive deficit and moderate neuropsychological dysfunctions due 
to organic brain damage have been reported in the early studies related to mental 
development of pediatric OLT recipients (11-13). Length of previous 
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hospitalizations, young age at onset of liver disease and poor nutritional status 
have been postulated to play a role in these deficits. It remains controversial as 
to whether developmental delay improves significantly after OLT (6). The 
constant need for medical supervision and daily use of immunosuppressive 
medication put these patients at risk of developing psychological problems 
similar to other patients with chronic illness (14). In general there is consistent 
agreement that children who have undergone OLT, may present emotional and 
behavioural disturbances (15,16). Some studies demonstrate the presence of 
psychological difficulties such as anxiety/depression, aggressiveness, mild 
cognitive deficits and school problems (15,17,18). There is still poor information 
on child's pysichological profile and physicosocial effects on family life well 
being following OLT (19-21). Our group has already given a preliminary 
contribute to evaluation of psychological impact on children who underwent 
liver transplantation. We suggested that the personality of OLT recipients was 
the result of two stressors: the early onset of chronic disease and the 
transplantation itself. These data also indicated that emotional and behavioural 
disturbances were often present long term after OLT (6). Subsequently, by using 
quantitative assessment methods, we confirmed in a small number of patients the 
hypothesis that children who have undergone OLT may present a 
psychopatological risk as compared with an age and gender matched control 
group affected by stable chronic liver disease (5). This risk, furthermore, seemed 
to exist for a long period of time after transplantation (5). In the present study  
we have confirmed in a larger series of OLT children our previous data. In fact 
CBCL evaluation has shown that they have an higher risk for behavioural and 
emotional disorders as compared to general and hepatopatic peers, and that both 
groups have reduced competences due to pathological Activity Scale results.  
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Difficulties observed in the social adjustment need further investigation by 
evaluating also quality of life (14). Concerning TMA, low scores  found in the 
Academic scale underline the existence of  lower school activity performances in 
OLT patients who may therefore require a special support. 
In conclusion, our results are in tune with the concept that the success of 
liver transplantation should not be measured only by survival rates. Its outcome 
will need to be judged using a measure which incorporates both survival rates 
and several features of children life including  psychological and social well 
being as well.  
 Understanding of the interaction between OLT and patient’s 
psychopathological risk and long-term health needs after liver transplantation is 
necessary to offer anticipatory guidance and targeted interventions. 
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CONCLUSIONS 
WHAT THESE STUDIES ADD TO THE CURRENT KNOWLEDGE AND 
WHAT ARE THE RECOMMENDATIONS FOR FUTURE RESEARCH 
 
A key purpose of this research is to contribute to a better management of 
children affected by liver disease by exploring several pathogenetic, diagnostic 
and natural history aspects. Our project is thus a series of essays, each of which 
evaluates and synthesizes data to generate a knowledge of several unclear 
aspects that might be applied to clinical practice. Therefore, each chapter is 
intended to highlight particular and emerging facets of liver disease to improve 
available tools for the care of hepatopatic patients. Most of our data are not 
conclusive but we believe that may in part be already transferred to patients’ 
management and also be useful to trigger further research in this area as well.   
1.  Regarding the study of genetic prothrombotic risk factors in children 
with extrahepatic portal vein obstruction, we have shown that a congenital 
condition of thrombophilia is found in one third of these patients, suggesting that 
prothrombotic disorders may be involved in the development of childhood PVT. 
Pediatricians ensuring the long-term follow-up of infants needing neonatal 
intensive care should consider the possibility of PVT in their patients. In our 
series it is interesting to note that pre-existing stress of portal vein by catheterism 
seems to facilitate development of PVT expecially in genetically predisposed  
individuals. Differently from adults V617F JAK2 probably does not play a role  
in childhood PVT. Understanding of thrombophilic genetic factors predisposing  
to PVT could be decisive to identify at risk patients subgroups and prevent other  
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possible thrombotic events also in different districts. This may lead to approach 
these patients appropriately so that their quality of life can be improved.  
Since patients’ number of previous studies deals with small series and no 
definite conclusions may be drawn, to gain a better insight into pathogenesis 
future research should be performed on large scale projects. Further evaluation 
of the V617F and possibly exon 12 JAK2 are recommended to assess their 
potential pathogenetic role and to recognize patients who probably should be 
carefully observed for the subsequent overt MPD.   
2. As for prevalence and long-term course of macro-aspartate 
aminotransferase (macro- AST) in children, our study is the first that has hitherto 
evaluated these issues. Given the large number of enrolled children, we were 
able to calculate with reasonable accuracy the prevalence of macro-AST (more 
than one third cases) among children with  isolated abnormal serum AST levels. 
The lack of pathological correlates over a long period argues for the benign 
nature of this phenomenon in childhood. We identified polyethylene glycol 
(PEG) precipitable activity (%PPA) thresholds vs. electrophoresis, the gold 
standard diagnostic test. Our % PPA thresholds will allow to use this tecnique as 
a simple and precise screening test, electrophoresis being reserved for 
confirming positive screen tests and cases in which %PPA levels are of 
intermediate discriminant accuracy. Physicians should be aware of the 
asymptomatic macro-AST phenomen in the absence of a disease state and also 
to consider this diagnostic possibility at an early stage when studying patients 
with isolated, raised AST. Prior documentation of macro-AST condition in a 
patient should be given the same prominence in a patient’s medical record as 
drug allergies. This way, invasive, costly, or ever, potentially life-threatening 
investigations (e.g. needle liver biopsy) or treatment may be averted. Moreover, 
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it is important to reassure affected children and their families that –according to 
our results- macro-AST has a good evolution and does not require any specific 
treatment.  
Future research on larger series of patients should evaluate the applicability and 
validity of our % PPA thresholds.  
3. Our prospective study on clinical utility of electrophisiological 
evaluation in Crigler-Najjar  syndrome has shown that only 
electroencephalogram (EEG) and visual evoked potentials (VEPs) findings 
correlate with high bilirubin levels. EEG and VEPs therefore may prove useful 
to identify and monitor neurotoxic effects of hyperbilirubinemia.  
 Our study is unique in paediatrics because neurological investigations of CN 
syndrome have been performed only in children and adolescents with type I CN. 
Neurophysiologic tests, in particular VEPs, may be useful for clinical 
management of patients with severe CN to identify and monitor neurotoxic 
effects of marked hyperbilirubinemia. They may contribute to choose the 
appropriate timing for addressing CN patients to OLT evaluation before 
catastrophic neurologig impairment happens. This may be particularly useful in 
those CN type II cases who have very severe hyperbilirubinemia poorly 
responsive to phenobarbital when some hesitation for liver transplantation exists 
on the part of doctors and patients and/or their families as well.  
 Future research should address better characterization of intermediate I/II 
phenotype CN. More precise delineation of possible relation among individual 
symptoms, genetic mechanisms, neurological signs and therapy response should 
be attempted to provide better targets for more tailored therapeutic interventions. 
Because of social aspects of jaundice among adolescents, more attention to this 
issue should also be paid.  
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4. 5. The last two studies who are part of this thesis regards two emerging 
complications of pediatric liver transplantation (OLT). 
4. As for post-transplant erythhrocytosis, the development of erythrocytosis in 
pediatric age has never been reported after OLT. We identified for the first time 
five cases (2 with high erythropoetin levels) who developed erythrocytosis in the 
long term follow-up. Causes of primary and secondary erythrocytosis, including 
mutations of erythropoietin-receptor, JAK2 and oxygen sensing pathway genes, 
were accurately excluded. In one patient erythropoietin production was much 
probably related to presence of renal cysts. In the remaining patients the 
mechanisms underlying erythrocytosis remains unknown. Since the rarity of  
erythrocytosis post-OLT (it  has never been described), close collaboration 
between colleagues and medical institutions taking care of these patients will be a 
prerequisite for future identification of this disorder.  
 The detection of erythrocytosis post-OLT has several important clinical 
implications. From a clinical point of view its recognition and treatment are 
important for maintaining Hct in a safe range to reduce the clinical symptoms 
and/or to minimize the possible risk of hyperviscosity related thrombosis. From an 
investigational point of view, this possible OLT complication should be taken into 
consideration in follow-up laboratory programs of liver transplant children. The 
increasing knowledge about molecular mechanism and the possibility that  
congenital mutations concerning candidate genes of primary and secondary 
erythrocytosis will essentially contribute to identify potential etiological factors.  
 Future research should therefore address  framework designs to produce a 
collaborative observational trial on erythrocytosis post- OLT in pediatric age. It is 
important to define  prevalence, clinical presentation, biochemical markers and 
treatment of this disorder in childhood. Since molecular analysis of the most 
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common genes responsible of congenital erythrocytosis has been performed on 
the patient’s lymphocites, we propose to analyze their mutations also on hepatic 
tissue to evaluate if erythrocytosis derive from liver donor. 
5. Regarding self-concept and psycopathological risk in liver transplantated 
children it is now becoming clear that the success of liver transplantation should 
not be measured only by survival rates. Its outcome will need to be judged by the 
amount of psychological aspects. We have confirmed on a larger series that OLT 
patients have an higher risk for behavioural and emotional disorders as compared 
to age matched controls with stable chronic liver disease. Lower performances in 
activity school have been demonstrated as well. As a consequence, our results 
highlight the fact that understanding of the interaction between OLT and patient’s 
psychopathological risk and long-term health needs after liver transplantation is 
necessary. This may help in  offering anticipatory guidance and targeted 
interventions, such as a school special support and psychological guidance. Our 
study might also be useful to create specific competences related to a integrated 
pediatric-psychosocial approach to liver transplanted children.  
Future research should try to identify methods to better discover OLT patients at 
risk for psychopathological complications. Integrations of  psychological 
interventions  in usual therapeutic protocols of  liver transplantated children are 
needed as well. Finally, because pediatric OLT seems to have a negative impact 
on some aspects of quality of life, this aspect also needs to be explored. Existing 
data are uncertain because of the small number of  studies conducted in short-term 
follow-up, and their variable quality.  
